P2Y12 inhibitor pretreatment in acute coronary syndrome — ESC · 2023 recommendation
2023 ESC acute coronary syndromes guideline
Routine P2Y12-inhibitor pretreatment is not recommended for NSTE-ACS when coronary anatomy is unknown and an early invasive strategy is planned.
Class of Recommendation
Class III
Level of Evidence
Level A
Last source-check date
2026-08-23
Exact source location
Recommendation Table 5, ‘Antiplatelet and anticoagulant therapy in acute coronary syndrome’, p. 3758
Prepared source-record governance
This record is prepared from a stored source. It is not labelled reviewer-verified because named reviewer provenance has not been documented.
- Clinical reviewer
- Not yet documented.
- Reviewer credentials
- Not yet documented.
- Last source-check date
- 2026-08-23
- Second-review status
- Not yet documented.
- Conflict-of-interest declaration
- Not yet documented.
- Source publication date
- Not yet documented.
- Source access date
- Not yet documented.
- Record version
- Not yet documented.
- Change history
- Not yet documented.
- Next review date
- Not yet documented.
Verification status & editorial record
Status: Prepared source record — reviewer provenance not documented.
Last source-check: 2026-08-23
No formally approved public metadata is currently available for a named reviewer, second-review status, conflict declaration, publication or access date, version history, or next review date for this record.
Verification boundary: This concise reference is limited to a prepared source recommendation. Verify the official document, local protocol, and patient context before application.